|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Division of Pulmonary and Critical Care Medicine (Drs. Diaz, Wewers, Wade, and Clanton, and Ms. Hart), Department of Internal Medicine, and Department of Radiology (Mr. King), The Ohio State University, Columbus, OH.
Correspondence to: Philip T. Diaz, MD, 201 Heart Lung Research Institute, 473 W. Twelfth Ave, Columbus, OH 43210; e-mail: diaz-1{at}medctr.osu.edu
| Abstract |
|---|
|
|
|---|
Design: Cross-sectional evaluation of a prospective, longitudinal study.
Setting: University teaching hospital.
Subjects/measurements: HIV-seropositive subjects without AIDS-related pulmonary complications participating in a descriptive study of lung biology in HIV-seropositive individuals. Emphysema scoring and evaluation of emphysema lobar distribution was performed among 40 subjects with emphysema. Eleven subjects underwent BAL of the right middle lobe (RML) and right upper lobe (RUL) with measurement of epithelial lining fluid (ELF) GSH in each lobe.
Results: We found that the mean emphysema scores were much higher in the upper lobes compared to the rest of the lung. Mean GSH levels were significantly greater in the RUL compared to the RML. The regional differences were present in both smokers and nonsmokers.
Conclusions: We conclude that in the setting of HIV, emphysema is more prominent and lung GSH concentrations are higher in the upper lobes. We hypothesize that the increased GSH may represent a compensatory response to increased oxidant stress in the upper lobes.
Key Words: emphysema glutathione high-resolution chest CT HIV lung oxidant stress
| Introduction |
|---|
|
|
|---|
In a study2 involving chest high-resolution CT (HRCT), we reported that HIV-seropositive individuals have higher total emphysema scores than age- and smoking-matched control subjects. In the current study, we reviewed this HRCT data to delineate the regional distribution of emphysema in the HIV-seropositive population. After finding a predilection for disease in the upper lobes, we then asked whether regional differences in oxidant stress might exist in the lungs of individuals with HIV. To address this question, we examined concentrations of glutathione (GSH), a ubiquitous antioxidant, in the epithelial lining fluid (ELF) of different lung regions.
| Materials and Methods |
|---|
|
|
|---|
Distribution of Emphysema on HRCT
Clinical characteristics of individuals (n = 114) involved in the HRCT substudy have been previously described.2 Previously, we reported the incidence of emphysema among subjects with the most substantial changes of emphysema (n = 17).2 In the present study, we delineate the anatomic distribution of emphysema among individuals with any emphysema detected (n = 40). For comparison, we also evaluated the anatomic distribution of 14 HIV-seronegative subjects participating in HRCT substudy2 with any emphysema detected.
Chest CT was performed with a GE9800 CT scanner (GE Medical Systems; Milwaukee, WI) or a Picker PQ 2000 CT scanner (Picker International; Solon, OH) with 1.5-mm collimation at 10-mm intervals. Scans were obtained at total lung capacity. Images were reconstructed using the high-spatial-frequency algorithm and were photographed at a lung window width of 1,500 Hounsfield units (brightness level, 700 Hounsfield units). Scans were read by two chest radiologists blinded to HIV status and clinical information. Emphysema was considered present if there was evidence of bullae, thin-walled cystic spaces, or abnormal decreases in attenuation, accompanied by vascular disruption. Emphysema severity was estimated by assigning an emphysema score (0 to 10) for each lobe according to the percentage of the lobe that was affected. For this analysis, the lingula was considered a separate lobe. The frequency of detection of emphysema in the various lobes as well as the total scores of the individual lobes were recorded.
Regional GSH Concentrations
We recruited 12 subjects for BAL of the RUL and RML. In one subject, lavage could not be analyzed because of insufficient return. This subject was excluded from analysis.
Bronchoalveolar Processing
Lavage fluid was processed as previously described.6 Five 20-mL aliquots of sterile saline solution were instilled into a distal segment of the RML and subsequently aspirated back into suction traps. The bronchoscope was then redirected into a distal segment of the RUL, where the procedure was repeated. Lavage fluid was immediately filtered through surgical gauze and centrifuged to separate cellular and noncellular components. Using 4 µmol/L 50% 5-sulfosalicylic acid, the supernatant was acidified to a pH of 5.5 and immediately assayed for total GSH using the recycling assay of Sies and Akerboom.7 The volume of ELF was estimated by the urea dilution technique.8
Data Analysis
Differences in emphysema scores among the various lobes were analyzed by analysis of variance. Group mean differences in GSH levels between the upper and middle lobes were analyzed by paired t test. Correlations were performed using a Spearman correlation. Data represented are group means ± SE.
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
A weakness of our study involves the relatively small number of subjects recruited for double-lobe lavage and measurement of ELF GSH. Nevertheless, BAL is an invasive procedure and was done entirely for research purposes. In addition, the differences between upper and middle lobes were highly significant, and similar changes were seen in both smokers and nonsmokers. Furthermore, 10 of 11 subjects had higher GSH levels in the upper lobes compared to the middle lobes. Thus, despite the relatively small numbers, we believe the regional differences in GSH concentrations are real.
We hypothesize that the increased GSH concentrations in the upper lobes represents an adaptive response to a chronic increase in oxidant stress in this region of the lung, as both in vitro and in vivo data suggest that chronic exposure to oxidant stress increases lung GSH secondary to induction of GSH synthesis.9 For example, in vitro data have demonstrated that oxidant stress produced by a variety of sources, including hyperoxia, initially results in a decrease, followed by a sustained increase in GSH levels in alveolar and bronchial epithelial cells.1011 This increase appears to be secondary to up-regulation of
-glutamylcysteine messenger RNA.9 Similarly, 90-day exposure to ozone in an in vivo model results in a 64% increase in GSH in distal bronchioles in both rats and monkeys.12 Indeed, such an adaptive response to chronic oxidant stress has been suggested as a mechanism underlying the increase in GSH found in the ELF of long-term cigarette smokers.9
Our data do not address the etiology for increased GSH in the upper lung zones. However, it is interesting to note that both smokers and nonsmokers had increased GSH levels in the upper lobes compared to the middle lobes, suggesting that this difference is not merely a smoking-related phenomenon. One hypothesis may be related to higher oxygen tensions in the upper lobes resulting from higher ventilation/perfusion ratios. Alternatively, the upper zones may have greater exposure to inhaled toxins/pollutants causing relatively greater inflammatory cell trafficking with a resultant increase in oxidant stress.
The predilection for pulmonary emphysema to develop in the upper lobes in nonHIV-infected smokers is a well-recognized clinical phenomenon.131415 Although the etiology is unknown, a number of hypotheses have been provided.13 For example, there may be less effective clearance of inhaled material from the upper lobes. Another hypothesis relates to slower transit time of leukocytes in the upper lobes compared to the lower lobes. This may allow a longer time for leukocytes to secrete inflammatory mediators. Each of these scenarios may be associated with increased oxidant stress in the upper lobes, and is consistent with our findings.
Whether our findings in the HIV population have relevance to the non-HIV population is not known. However, the similar tendency to develop upper lobe disease suggests that our findings among HIV-seropositive individuals may have relevance to the general population of smokers.
| Footnotes |
|---|
Supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants RO1 49730 and RO1 53229, and The Ohio State University General Clinical Research Center grant MO1 RR00034.
Received for publication December 11, 2003. Accepted for publication May 26, 2004.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |